Antibiograms of Intensive Care Units at an Egyptian Tertiary Care Hospital
|ClinicalTrials.gov Identifier: NCT04318613|
Recruitment Status : Completed
First Posted : March 24, 2020
Last Update Posted : June 23, 2020
|Condition or disease|
Hospital Acquired Infections (HAIs) surveillance at the local and national levels is an essential component of its control and prevention. The highest prevalence of HAIs is in Intensive care units (ICUs) and it is associated with considerable negative impact on the patients' outcome with a marked increase in the treatment costs. Therefore, early appropriate antibiotic therapy is a fundamental part of the treatment of these patients and it can be lifesaving. However, bacteria are becoming more resistant with alarming rates of antibiotic resistance worldwide.
Antibiotic resistance is part of a broader threat called antimicrobial resistance (AMR) that includes resistance to medicines used to treat all types of infections, including those caused by bacteria, parasites, and fungi. ICUs are considered the epicenter of AMR development due to the severity of critical illness, patients are at high risk of becoming infected through the use of invasive devices (e.g. endotracheal tubes, vascular and urinary catheters), and the extensive antibiotic use with variable infection control practices. Consequently, management of infections in ICU is a growing challenge and ICU physicians should have regularly updated antibiograms in order to guide appropriate decisions about the choice of empirical antibiotics when waiting for culture results Antibiograms are reports that summarize the information of bacterial antibiotic susceptibility rates within a single facility over the duration of one calendar year. They are used in tracking bacterial resistance and guiding empirical antibiotics prescription within the facility.
With the high burden of AMR and the ample variety between ICUs in the prevalence of micro-organisms and their antibiotic susceptibility, it is crucial that the selection of empirical antibiotic therapy should be guided by ICU-specific antibiogram. Also, the emerging trends in bacterial resistance at the local level should be monitored regularly.
The aim of this study is to find out the prevalence and types of pathogens and to determine their antibiotic susceptibility and resistance in different ICUs of an Egyptian tertiary care hospital (Zagazig University Hospitals).
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||45221 participants|
|Target Follow-Up Duration:||10 Days|
|Official Title:||Antibiograms of Intensive Care Units at an Egyptian Tertiary Care Hospital|
|Actual Study Start Date :||January 1, 2019|
|Actual Primary Completion Date :||December 31, 2019|
|Actual Study Completion Date :||December 31, 2019|
- Prevalence of micro-organisms at an Egyptian Tertiary Care Hospital [ Time Frame: one year ]the prevalence and types of micro-organisms in Zagazig University Hospitals' ICUs by using data record base.
- generation of ICU specific antibiogram [ Time Frame: one year ]prepare and interprete antibiograms to guide empirical antibiotics prescription at ICUs of zagazig university hospitals by data record base cross sectional study
- the incidence of antibiotic susceptibility and resistance pattern of these micro-organisms [ Time Frame: one year ]the incidence of each antibiotic susceptibility and resistance pattern of micro-organisms at Zagazig University Hospitals' ICUs by record base study.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04318613
|Emergency, Surgical Intensive Care Units,medical, pulmonary, coronary, neonatal, and pediatric ICUs-Zagazig University Hospitals|
|Zagazig, Sharkia, Egypt, 44111|
|Principal Investigator:||Sherif M Mowafy, MD||Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University|
|Study Director:||Essamedin M Negm, MD||Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University|
|Principal Investigator:||Ahmad A Mohammed, MD||Clinical Pathology Department, Faculty of Medicine, Zagazig University|
|Principal Investigator:||Tarek H Hassan, MD||Chest Department, Faculty of Medicine, Zagazig University|
|Principal Investigator:||Marwa G Amer, Master||Clinical Pathology Department, Faculty of Medicine, Zagazig University|
|Principal Investigator:||Ahmed E Tawfik, Bachelor||Clinical pharmacist, Zagazig University Hospitals|